Detalles de la búsqueda
1.
Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.
Am J Hematol
; 93(10): E342-E345, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30054949
2.
A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry.
Am J Hematol
; 92(7): E125-E128, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28376561
3.
Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience.
Leuk Lymphoma
; 63(9): 2213-2223, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35491715
4.
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs.
Blood Adv
; 6(17): 5171-5183, 2022 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35802458
5.
Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study.
Clin Lymphoma Myeloma Leuk
; 17(5): 283-295, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28185798
6.
Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry.
Clin Lymphoma Myeloma Leuk
; 18(7): e283-e285, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29778693
Resultados
1 -
6
de 6
1
Próxima >
>>